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CObjectives: Pharmacy-based drug utilization reviews were conducted
through the Brown Bag program to understand drug-use patterns,
identify potential safety concerns, and provide appropriate consulta-
tion for elderly individuals. Methods: Community pharmacists in Hir-
oshima, Japan, participated in this review program from October to
December 2009. Elderly individuals, 65 years or older, were recruited
from community events or at pharmacies and were asked to bring all
their prescription and nonprescription drugs including over-the-coun-
ter drugs and dietary supplements to the program. Pharmacists re-
viewed the medications and their usages and gave appropriate feed-
back if medications were used incorrectly, had potential interactions,
or had safety concerns. The relationships among medication usage,
participant responses, and potential safety concerns were analyzed by
using logistic regression models. In addition, contraindications, dupli-
cate medications, and potentially inappropriate medications were de-
scriptively analyzed. Results: Drug utilization reviews were con-
ducted on 508 elderly participants at 177 community pharmacies. Of O
e no
tical
al So
oi:10.1016/j.vhri.2012.03.001he 508 participants, 53% were 75 years old or older and 34% were
en. Twenty-four percent of the elderly participants used prescrip-
ion drugs only, and 73% used both prescription and nonprescription
rugs. Pharmacists offered feedback to 250 participants (49%) concern-
ng the risk of duplication/interaction, possible adverse drug reaction
hat can be averted, inappropriate/unnecessary medication, nonad-
erence, and overdose. Two cases of contraindicated drugs, 3 cases of
uplicatemedications, and 327 cases of potentially inappropriatemed-
cations were identified. Conclusions: The drug-use patterns among
lderly individuals were identified. This medication review program
onducted at community pharmacies was a useful approach to reduce
oncerns among users and prevent safety problems.
eywords: community pharmacist, drug utilization review, elderly,
otentially inappropriate medication.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Many patients, particularly the elderly, take multiple medications
concurrently for the treatment of a variety of acute and chronic
conditions. Takingmultiplemedications is associatedwith poten-
tial drug-related safety problems [1,2]. A drug utilization review
revealed that among elderly Americans, 29% used at least five
prescription drugs concurrently, 46% used over-the-counter (OTC)
drugs, and 52% used dietary supplements in addition to prescrip-
tion drugs [3]. Among the multiple medication users, approxi-
mately 1 in 25 had a concern about potential major drug interac-
tions. A similar tendency of overlapping medication usage was
reported through a telephone survey expressing a potential con-
cern for unintended interactions [4]. In Japan, potential safety con-
cerns related to drug utilization have been analyzed by using large
databases [5,6]. Patient-oriented information, including usage of
nonprescription drugs such as OTC drugs and dietary supple-
ments, however, is limited.
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ublished by Elsevier Inc.A medication review provided at a community pharmacy is a
great method to reach the elderly population in the community to
evaluate the usage of both prescription and nonprescription drugs
[7,8]. Elderly patients were asked to bring all theirmedications to a
participating pharmacy for review. The pharmacist then system-
atically checked the medications to identify the potential safety
concerns, such as contraindications, interactions, compliance, in-
appropriate usage, or adverse drug reactions, and educated the
patients about their diseases and medications in a face-to-face
interview. This pharmacy-basedmedication review program is of-
ten referred to as Brown Bag because of an earlier program con-
ducted in the United States in which pharmacists instructed pa-
tients to bring their medications in a brown paper bag [9], and
currently, it has become a key component of the medication ther-
apy management program for Medicare beneficiaries [10,11].
The Hiroshima Pharmaceutical Association conducted the
Brown Bag program as a part of health promotion activities in the
community. The Hiroshima prefecture is located in the western
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Japanese population), 21% were 65 years or older according to the
2005 census [12]. Themajority of the elderly living in this areawere
survivors of the atomic bomb tragedy, and in 2007, their annual
medical expenditure was 15% higher than the national average
[13]. The regional health care council, which consisted of the Hir-
oshima prefecture, Hiroshima city, Hiroshima University, and the
Hiroshima Medical Association, supported the community pro-
gram to understand drug-use patterns among citizens and to
achieve appropriate use of medical resources [14].
As a research team from the University of Tokyo, we collabo-
rated with the Hiroshima prefecture to support the medication
review program, develop data collection procedures, and conduct
data analyses. In this study, we described the drug-use patterns
and potential safety concerns among the elderly population in
Hiroshima. We also evaluated the views of the recipients on the
pharmacy-based services.
Methods
Data collection
Community pharmacists, as members of the Hiroshima Pharma-
ceutical Association, recruited elderly individuals aged 65 years or
older to participate in the review program at their pharmacies or
community health events from October to December 2009. In ad-
dition, advertisements through news releases, poster displays in
the community, and local government and professional organiza-
tion Web sites were used to increase the program awareness
among individuals who did not visit pharmacies regularly. We
distributed an originally developed promotion kit to the pharma-
cists; this kit contained a participant brochure, a poster, and a
shopping bag with the program logo (Fig. 1). We also prepared
standardized data collection sheets for conducting a systematic
medication review and for maintaining the necessary records (see
Appendix 1: Participant background and feedback sheet, and Ap-
pendix 2: Medication review sheet, in Supplemental Materials
found at doi: 10.1016/j.vhri.2012.03.001).
Elderly individuals were asked to contact their neighborhood
harmacy, possibly by appointment, and bring all their medica-
ions that were regularly used at home including prescription and
onprescription drugs (i.e., OTC drugs and dietary supplements).
harmacists checked and recorded drug information (brand
ame, pharmaceutical company name, and active ingredients),
rom where the medication was obtained, duration of use, reason
or choosing nonprescription drugs, and usage during the last
Fig. 1 – Brown Bag program promotion kit.eek (such as storage, frequency, and adherence) for each medi-cation. If contents of the drug were unidentifiable, detailed drug
information or a picture of the package was collected for further
investigations. All records were maintained in the medication re-
view sheet.
When the pharmacists found any potential safety concerns
regarding the medications and their usage, they were categorized
into any of the following five potential concerns: 1) potential du-
plication/interaction, 2) overdose, 3) potentially inappropriate/un-
necessary medication use, 4) complicated medication use/risk of
nonadherence, or 5) potential risk of adverse drug reaction. The
pharmacists then discussed potential safety concerns with partic-
ipants and provided appropriate feedback. This feedback session
was given immediately after the review (recommended) or at the
next visit. Additional information such as age, sex, insurance pro-
gramdetails, number ofmedical institutions regularly visited, and
self-reported health conditions (16 specific conditions or others)
was collected because it could influence the drug-use patterns.
The insurance program was classified into the following four
types: 1) insurance program for 75 years or older individuals (co-
payment rate for medications is generally 10%), 2) local govern-
ment-run insurance program (called “National Health Insurance”
and its co-payment rate is 30%), 3) employee-based insurance pro-
gram (called “Social Health Insurance” and its co-payment rate is
30%), and 4) others [15].
To analyze the effectiveness of the pharmacy-based services,
the time spent by the pharmacist for the medication reviews and
participant’s experience receiving them were recorded. Pharma-
cists checked any of the specified four positive (better understand
instructions for drug use, get confirmation of appropriate medica-
tions, ease concerns about interactions and adverse drug reaction,
and ease concerns about duplication) and three negative re-
sponses (tiresome to bring all medications from home, takes too
much time, and insufficient advice), if applicable, or commented
in detail. Multiple responses from participants were allowed. A
positive responder was defined as a participant who expressed at
least one positive response, and a negative responder was defined
as a participantwho expressed at least one negative response. The
reasons why participants made particular responses were also re-
corded. All recordsweremaintained by using the participant back-
ground and feedback sheet.
Participants received the one-time medication review at phar-
macies free of charge and were asked for their permission to use
the data for our analyses. Information entered in the data collec-
tion sheets was deidentified at pharmacies (no individual name
and address was included) and sent to the University of Tokyo by
the Hiroshima Pharmaceutical Association. Researchers at the
university conducted data entry andmaintained the database. All
drug names were converted to individual drug codes called the YJ
codes that could be transformed into ingredient data and accord-
ingly classified in compliancewith the Japan StandardCommodity
Classification system [16]. A combination prescription drug has its
own YJ code, whereas we assigned YJ codes to each component of
OTC drugs (e.g., an OTC drug that included six active ingredients
was represented by six drug codes). This study was approved by
the Institutional Review Board at the researcher’s institution and
was conducted in compliance with the Japanese Ethical Guide-
lines for Epidemiological Research updated in November 2007 [17].
Data analyses
We analyzed the data in two steps. First, we descriptively summa-
rized the data reported by the community pharmacists. For each
participant, the number of medications, prescription drugs, OTC
drugs, and dietary supplements was counted. Drug-use patterns
of participants were classified into prescription drugs only, pre-
scription and nonprescription drugs, and nonprescription drugs
only. Participant characteristics, potential safety concerns identi-
fied by pharmacists, and positive and negative responses reported
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with thedrug-use patterns. Theassociationsofpotential safety con-
cerns and responses with the drug-use patterns were analyzed by
using logistic regressionmodels adjusted for age (75 years/not), sex
(man/woman), and number of prescription drugs (five or more/not)
andweredescribedwithodds ratio (OR)with95%confidence interval
(CI). Reasons for positive and negative responses were summarized
from the comments provided by pharmacists or participants.
Second, we retrospectively analyzed potential safety concerns
by using the database. Major drug interactions and duplicates
were identified by using the YJ codes and a drug information da-
tabase developed by System Yoshii Co., Ltd. (Okayama, Japan).
Contraindications were identified on the basis of Japanese pack-
age insert information of the prescription drugs. Duplicate medi-
cations were defined as drugs with the same YJ code prescribed
with different brand names or fromdifferent prescribers. Potentially
inappropriatemedicationswere evaluatedbyusing theBeers criteria
developed for the Japanese elderly population [18–20].When the po-
tential safety concerns were identified by the database analyses,
detailed information of participants and feedbacks provided by
the pharmacists were extracted from the data collection sheets.
Fig. 2 – Drug-use patterns among elderly individuals. Rx,
prescription drugs; non-Rx, nonprescription drugs which
include over-the-counter drugs (OTC) and dietary
supplements (SUP).
Table 1 – Participant characteristics.
Characteristics Al
Age (y), mean  SD
65 y old or younger, n (%)
65–74 y old, n (%)
75 y old or older, n (%)
Not reported
Sex, man, n (%)
Insurance programs, n (%)
Health insurance for elderly people (75 y or older)
National health insurance
Social health insurance
Other
Number of medical institutes (regularly visit), mean  SD
Self-reported health conditions, n (%)
Hypertension
Hyperlipidemia
Gastritis or stomach ulcer
Eye disease
Heart disease
Osteoporosis
Backache
Diabetes
ArthritisNote. Nonprescription drugs include over-the-counter drugs and dietary sAll analyses were conducted by using IBM SPSS Statistics Soft-
ware, version 18 (SPSS, Inc., Chicago IL).
Results
In the Brown Bag medication review program in the Hiroshima
prefecture, pharmacists in 177 community pharmacies conducted
reviews of 508 participants for 3 months. The number of partici-
pants in each pharmacy varied from 1 to 60. The average number
of medications used by a participant was 8.0 with an SD of 4.5 and
a range of 1 to 25. For each medication category, 494 (97.2%) par-
ticipants used at least one prescription drug, 182 (35.8%) used at
least one OTC drug, and 282 (55.5%) used at least one dietary sup-
plement. The average number of medications for each category
user was 6.2 (SD 3.8; range 1–20), 1.6 (SD 0.9; range 1–6), and 1.8 (SD
1.4; range 1–10), respectively.
The details of the concomitant usage of medications are sum-
marized in Figure 2. Among the 508 participants, 122 (24.0%) used
prescription drugs only and 14 (2.8%) used nonprescription drugs
only. Along with prescription drugs, 372 (73.2%) participants con-
comitantly used nonprescription drugs, including OTC drugs (103
users), dietary supplements (195 users), or both (74 users). Amajor
reason given by the participants to the pharmacists for selecting
certain nonprescription drugs was recommendation from phar-
macists, family members, and friends. Because of the small sam-
ple size of the users of nonprescription drugs only, we summa-
rized the data for all participants (n  508), users of prescription
drugs only (n  122), and users of both prescription and nonpre-
scription drugs (n  372) for further analysis.
The characteristics of the participants are summarized in
Table 1. Fifty-three percent of all participants were 75 years old or
older and 34% were men, which is less than the percentage of
elderly men in the Hiroshima prefecture (42%). Participants who
used nonprescription drugs tended to be women and had self-
ticipants
508)
Prescription
drugs only
(n  122)
Prescription and
nonprescription drugs
(n  372)
 9.4 74.1  10.0 74.6  8.9
(8.3) 8 (6.6) 30 (8.1)
(37.0) 47 (38.5) 137 (36.8)
(53.3) 67 (54.9) 198 (53.2)
(1.4) 0 7 (1.9)
(34.1) 55 (45.1) 115 (30.9)
(51.2) 61 (50.0) 196 (52.7)
(33.1) 44 (36.1) 117 (31.5)
(12.2) 13 (10.7) 46 (12.4)
(3.5) 4 (3.3) 13 (3.5)
 0.9 1.8  0.9 1.8  0.9
(58.5) 65 (53.3) 229 (61.6)
(34.1) 37 (30.3) 134 (36.0)
(23.2) 25 (20.5) 91 (24.5)
(20.1) 20 (16.4) 76 (20.4)
(17.9) 21 (17.2) 69 (18.5)
(17.1) 15 (12.3) 70 (18.8)
(15.0) 14 (11.5) 59 (15.9)
(13.2) 15 (12.3) 50 (13.4)
(13.0) 8 (6.6) 57 (15.3)l par
(n 
74.3
42
188
271
7
173
260
168
62
18
1.8
297
173
118
102
91
87
76
67
66upplements.
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tistical analysiswas not conducted). The drug-use patterns did not
vary in participants with different insurance programs and their
number of medical institutions. The average time used for the
medication reviews was reported by pharmacists. They spent an
average of 15.7 minutes (SD 10.8) for each review, and the time
tended to increase if a participant used many concomitant medi-
cations or dietary supplements. They spent an average of 9.4 min-
utes (SD 6.9) for feedback. The feedbackwas given on the sameday
(65%), at the next visit (31%), or not specified (4%).
The participants’ responses are summarized in Table 2. More
than 90% of the participants expressed having any of the five
positive responses and 45% of them expressed having any of the
four negative responses. Because multiple answers were al-
lowed, the total exceeded 100%. The ORs were calculated to
predict the likelihood of reporting each positive or negative re-
sponse for participants who used both prescription and nonpre-
scription drugs compared with those who used prescription
drugs only. Statistically significant associations were observed
for two positive responses. Participants who used both prescrip-
tion and nonprescription drugs were more likely to express that
the review reduced concerns about interaction and adverse
drug reaction (OR 1.90; 95% CI 1.24–2.90) and less likely to ex-
press that it confirmed appropriate medications for their dis-
ease conditions (OR 0.63; 95% CI 0.42–0.96). Participants pro-
Table 2 – Participant response regarding experience of the
Participant response All participan
(n  508)
Positive, n (%) 473 (93.1)
Ease concerns about interactions and adverse
drug reaction
257 (50.6)
Get confirmation of appropriate medications 216 (42.5)
Better understand instructions for drug use 188 (37.0)
Ease concerns about duplication 122 (24.0)
Others 16 (3.1)
Negative, n (%) 230 (45.3)
Tiresome to bring all medications from home 181 (35.6)
Takes too much time 40 (7.9)
Insufficient advice 14 (2.8)
Others 25 (4.9)
Note. Odds ratio (OR) and 95% confidence interval (CI) were calculate
for participants who used both prescription and nonprescription d
regression models were used, adjusted for age, sex, and number of
excluded from estimating OR because of small sample size (n  14).
Table 3 – Potential safety concerns identified by pharmacis
Potential safety concerns All parti
(n 
Any of safety concerns, n (%) 250 (
Potential duplication/interaction 101 (
Potential risk of adverse drug reaction 75 (
Potentially inappropriate/unnecessary medication use 53 (
Complicated medication use/risk of nonadherence 52 (
Overdose 24 (
Note. Odds ratio (OR) and 95% confidence interval (CI) were calculated
participants who used both prescription and nonprescription drugs c
models were used, adjusted for age, sex, and number of prescription
estimating OR because of small sample size (n  14).vided several reasons supporting their positive or negative
responses. Some participants indicated that they could not ob-
tain sufficient information about their medications and disease
conditions during their usual care and that the review was use-
ful to them. Others expressed that it was a good opportunity to
reduce the fear of interactions or harmful effects for self-se-
lected medications. In contrast, the negative reasons included
increased time to receive a review result.
The potential safety concerns identified by pharmacists are
summarized in Table 3. Pharmacists found any of the five pre-
specified concerns and provided feedback to 250 (49.2%) partici-
pants. Some participants had multiple potential problems. A ma-
jor finding was that 101 (19.9%) participants had a potential
duplication/interaction. Other typical examples were multiple
combinations of nonsteroidal anti-inflammatory drugs, overdose
of benzodiazepines, overuse of dietary supplements, and compli-
cated medication use in the treatment of osteoporosis as well as a
diabetes-related eye disorder. The adjusted ORs indicated that no
significant association was observed between drug-use patterns
(use of prescription and nonprescription drugs compared with
that of prescription drugs only as a reference category) and poten-
tial safety concerns.
The results of the database analyses are summarized in Table
4. Because only two cases of contraindications and three cases of
duplicates were observed, detailed information of participants
n Bag program.
Prescription
drugs only
(n  122)
Prescription and
nonprescription drugs
(n  372)
OR (95% CI)
113 (92.6) 350 (94.1) 1.26 (0.41–1.85)
47 (38.5) 206 (55.4) 1.90 (1.24–2.90)
62 (50.8) 148 (39.8) 0.63 (0.42–0.96)
49 (40.2) 136 (36.6) 0.84 (0.55–1.28)
23 (18.9) 97 (26.1) 1.50 (0.90–2.51)
3 (2.5) 13 (3.5) 1.55 (0.43–5.62)
51 (41.8) 173 (46.5) 1.26 (0.83–1.92)
39 (32.0) 138 (37.1) 1.30 (0.83–2.02)
6 (4.9) 31 (8.3) 1.87 (0.76–4.64)
4 (3.3) 10 (2.7) 0.84 (0.26–2.79)
8 (6.6) 16 (4.3) 0.67 (0.28–1.63)
redict the likelihood of reporting each positive or negative response
compared with those who used prescription drugs only. Logistic
cription drugs. Participants using nonprescription drugs only were
nts Prescription
drugs only
(n  122)
Prescription and
nonprescription drugs
(n  372)
OR (95% CI)
53 (43.4) 193 (51.9) 1.43 (0.94–2.17)
20 (16.4) 78 (21.0) 1.41 (0.81–2.45)
15 (12.3) 59 (15.9) 1.38 (0.75–2.54)
9 (7.4) 43 (11.6) 1.65 (0.78–3.52)
14 (11.5) 38 (10.2) 0.85 (0.44–1.65)
2 (1.6) 22 (5.9) 3.70 (0.85–16.0)
redict the likelihood of reporting any of potential safety concerns for
red with those who used prescription drugs only. Logistic regression
. Participants using nonprescription drugs only were excluded fromBrow
ts
d to p
rugs
prests.
cipa
508)
49.2)
19.9)
14.8)
10.4)
10.2)
4.7)
to p
ompa
drugs
Table 4 – Potential safety concerns identified by the database analysis and detailed case description.
Case
ID
Description of potential
safety concerns
Patient characteristics OTC or SUP
use
Other prescription
drugs
Pharmacist
feedback
Age Sex Number of medical
institutions
Reported
conditions
422 Contraindication (bezafibrate
and rosuvastatin)
66 F 1 Asthma
Diabetes
Yes Epinastine
Fluticasone
Nilvadipine
Pioglitazone
Theophylline
No specific comments
were given
462 Contraindication (bezafibrate
and pravastatin)
78 F 1 Hyperlipidemia
Hypertension
Yes Nilvadipine
Tocopherol
Vitamin E supplement
Overuse of vitamin E
was indicated
141 Duplicate medications
(allopurinol was
prescribed with different
brand names)
68 M 3 Allergy
Dementia
Hyperlipidemia
Hypertension
Hyperuricemia
Osteoporosis
No Alprazolam
Amlodipine
Losartan
Mequitazine
Pravastatin
Sulpiride
Ticlopidine
Tranilast
Duplicate use was
indicated
374 Duplicate medications
(sennoside was prescribed
by different doctors)
77 M 3 Asthma
Bronchitis
Backache
Eye disease
Gastritis ulcer
Hypertension
Yes Amlodipine
Ecabet
Famotidine
Flavoxate
Fluticasone
Furosemide
Mecobalamin
Meloxicam
Levofloxacin
Nifedipine
Omeprazole
Procaterol
Theophylline
Tramazoline
Triazolam
Valproate
Valsartan
Duplicate use was
notified to doctors
and one medication
was terminated
501 Duplicate medications
(teprenone was prescribed
by different doctors)
91 F 2 Arthritis
Gastritis ulcer
Hypertension
Yes Alfacalcidol
Beraprost
Candesartan
Celecoxib Cilnidipine
Felbinac
Flunitrazepam
Imidafenacin
Ioxoprofen
Rabeprazole
Sennoside
Duplicate use was
indicated and
dosage schedule
was changed
M, male; F, female; OTC, over-the-counter drugs; SUP, dietary supplements.
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brate and statin, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitor was contraindicated for patients with a
renal disorder, and these should be carefully used to prevent seri-
ous myopathy and rhabdomyolysis [21]. Feedback, however, was
not provided for concomitant use in either case. Three cases of
duplicate medications (allopurinol, sennoside, and teprenone)
were noticed by pharmacists, and appropriate actionwas taken. In
addition, 327 potentially inappropriatemedications for the elderly
in 228 participants (45%) were identified by using the Beers criteria
for the Japanese elderly population (Table 5). According to the re-
cords on the feedback sheets, only 39 caseswere given appropriate
feedback, indicating that these medications were inappropriate.
Discussion
According to themedication review, elderly individuals in the Hir-
oshima prefecture concomitantly used an average of 6.2 different
prescription drugs. Approximately 59% of the participants used
five ormore prescription drugs, and 73% of themused prescription
and nonprescription drugs together. Compared with the previ-
ously reported pattern in the United States [3], Japanese elderly
individuals tended to use less OTC drugs andmore dietary supple-
ments. They were more likely to use five or more prescription
drugs for which a risk of polypharmacy-related problems might
increase [22]. To evaluate the generalization of findings, we com-
pared the prescription drug-use patterns with the pharmacy bill-
ing data maintained by IMS Japan K.K. (Tokyo, Japan). Among
28,028 patients (40% were 75 years old and 42% were men), the
mean number of different types of drugs used was 4.9 and 55%
used five or more drugs [23].
The review program provided a great opportunity to educate
patients about appropriate medication usage. We found that
many participants confirmed the appropriate usage of medica-
tions for their conditions and reduced concerns about interaction
and adverse drug reaction. The responses reported by participants
and potential safety concerns identified by pharmacists were
mostly independent of the drug-use patterns. It seemed that they
did not have an opportunity to discuss these concerns with phar-
macists evenwhen the prescription drugs were dispensed. In con-
trast, there were negative responses regarding the review time.
Some participants, particularly thosewho used a variety of dietary
supplements, mentioned that theywere rarely provided appropri-
ate feedback for their medication usage. In fact, the information
source for dietary supplements is limited, particularly for the con-
Table 5 – Potentially inappropriate medications for elderly
Drug names Number (%) of participants w
used the medication†
Etizolam 55 (16.8)
Famotidine 39 (11.9)
Triazolam 35 (10.7)
Flunitrazepam 25 (7.6)
Alprazolam 24 (7.3)
Sulpiride 18 (5.5)
Doxazosin mesilate 18 (5.5)
Ticlopidine hydrochloride 12 (3.7)
Ethyl loflazepate 10 (3.1)
* Potentially inappropriate medications were identified by using the
[20]. The table shows medications used by at least 10 participants.
† A total of 327 potentially inappropriate medications were identified
‡ According to the records on the feedback sheets, only 39 participant
inappropriate.comitant use with other medications.The results also suggest a limitation of the role of pharmacists
in the medication review. Without direct access to medical re-
cords, it is difficult to judge the appropriateness of the medication
choices. Evenwithoutmedical records, pharmacists could find po-
tential safety concerns and provide feedback to nearly half of the
participants. In fact, three cases of duplicate medications or med-
ications with different brand names prescribed by different phy-
sicians were identified by pharmacists. Most of the potentially in-
appropriate medication usage by the elderly population, however,
was not identified. One explanation was that a list of medications
was published in amedical journal in 2008 [20] but was not widely
accepted by community pharmacists. A guideline for the pharma-
ceutical management of high-risk medications for community
pharmacists was recently published [24]. The list of thesemedica-
tions was included; therefore, we expect this situation to improve.
The external validity of this study may have limitations. El-
derly individuals who participated in this program were recruited
primarily by community pharmacists or on recommendation from
family members or friends. Those participants may already have
established good relationships and communicationwith the phar-
macists so that potential medication problems may have been
identified and maintained in pharmacy records. Therefore, our
findings underestimated the true problems faced by the elderly in
a community. At the same time, participants who might have po-
tential safety concerns were more likely to seek the medication
review service to reduce their concerns. In this situation, the iden-
tified concernsmay have been overestimated. In fact, the compar-
ison with IMS data indicated that our study population was older
and used a greater variety of prescription drugs. Because the
BrownBag programhas been implemented in community projects
[8,9], we would continue this medication review as a community
service in Hiroshima and other areas by random sampling of el-
derly individuals living at home and/or in residential facilities to
identify the situation in Japan.
A goal of this study was to make the pharmacy-based medica-
tion review program a common practice among community phar-
macies across Japan. In addition to the Brown Bag program in the
United States, similar pharmacy-based services are provided in
other countries. For example, in the United Kingdom, Medicines
Use Review has been provided as an advanced service in commu-
nity pharmacies since April 2005 [25,26]. This is a free national
health servicewith a structured checklist, and detailed guidance is
provided to help community pharmacists. In Australia, the Medi-
cation Management Reviews by an accredited pharmacist have
been provided for the elderly who live in residential facilities or at
le*.
Number of participants to whom feedback was given
indicating that the medication was inappropriate‡
13
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4
1
2
4
1
0
criteria for the Japanese elderly population developed by Imai et al.
28 participants (45%).
e given appropriate feedback, indicating that thesemedicationswerepeop
ho
Beers
in 2
swerhome [27]. In Ontario, Canada, the MedsCheck programwas intro-
c[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
104 V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 9 8 – 1 0 4duced in 2007 [28]. To improve our program, we should learn from
the experiences of these countries that provide pharmacy-based
services, including advertisements for participant recruitment,
standard procedures, record maintenance, communication with
physicians and other medical professionals, and training pro-
grams to educate pharmacists. Moreover, to expand generaliza-
tion of the medication review results, we plan to develop a large
database of medication usage collected through the medication
review programs across various regions over time. In addition, by
using the medication data collected, we would like to develop a
drug information database that covers major nonprescription
drugs widely used in Japan. Because some pharmacists expressed
difficulty finding necessary information to check potential inter-
actions and safety concerns quickly, such a database is essential
for maintaining the quality of service independent of a pharma-
cist’s experiences and skills.
Conclusions
We identified drug-use patterns among the Japanese elderly pop-
ulation by using data collected through the Brown Bagmedication
review program in Hiroshima. Because many individuals tend to
have a complicated drug regimenwithmultiple prescription drugs
and dietary supplements, the medication review by community
pharmacists is a useful approach to reduce concerns among users
and prevent safety problems. By learning fromsimilar programs in
other countries, this program could be improved to make it more
user-friendly for pharmacists and to encourage individuals who
do not have regularmedication reviews to participate in this phar-
macy-based program.
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